Clinical Characteristics of Cryopyrin-Associated Periodic Syndrome and Long-Term Real-World Efficacy and Tolerability of Canakinumab in Japan: Results of a Nationwide Survey.
Takayuki MiyamotoKazushi IzawaSho MasuiAtsue YamazakiYuichi YamasakiTadashi MatsubayashiMayuka ShirakiHidenori OhnishiJunko YasumuraTomohiro KawabeTakako MiyamaeTomoyo MatsubaraNaoya ArakawaTakashi IshigeTakumi TakizawaAsami ShimboMasaki ShimizuNaoki KimuraYuichi MaedaYuta MaruyamaTomonari ShigemuraJunichi FurutaSatoshi SatoHiroshi TanakaMiharu IzumikawaMasahiro YamamuraToshio HasegawaHiroshi KanekoYasuo NakagishiNaoko NakanoYasunori IidaTamaki NakamuraHiroyuki WakiguchiTakayuki HoshinaToshinao KawaiKosaku MurakamiShuji AkizukiAkio MorinobuKoichiro OhmuraKatsuhide EguchiMotoshi SonodaMasataka IshimuraKenji FurunoMomoko KashiwadoMasaaki MoriKimito KawahataKoremasa HayamaKumiko ShimoyamaNatsuko SasakiTaisuke ItoHiroaki UmebayashiTae OmoriSeiko NakamichiTomotsune DohmotoYasuyuki HasegawaHisashi KawashimaShojiro WatanabeYuichiro TaguchiHaruna NakasekoNaomi IwataHiroki KohnoTaiki AndoYasuhiko ItoYuko KataokaTakako SaekiUtako KanekoAyako MuraseSeira HattoriTomo NozawaKenichi NishimuraReiji NakanoMisa WatanabeMasato YashiroTomonori NakamuraToshihiko KomaiKentaro KatoYoshitaka HondaEitaro HiejimaAtsushi YonezawaKazuhisa BesshoSatoshi OkadaOsamu OharaJunko TakitaTakahiro YasumiRyuta Nishikomorinull nullPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2024)
This study provides one of the largest epidemiologic data sets for CAPS. Although early initiation of anti-IL-1 treatment with canakinumab is beneficial for improving disease prognosis, some patients do not achieve remission despite a high serum concentration of canakinumab. Moreover, IBD may develop in CAPS after canakinumab treatment.
Keyphrases